Therapeutically, in prostate cancers, targeting Wnt3a through Traf6 either Tmem64 restrained tumor development.76,77 For liver cancers, targeting Wnt3a by miRNA-195 and miRNA‐214 presented the possibility of cancer management.78,79. Here, WNT3A is linked to neoplasm.